You are currently logged into
Cancer Health Directory - My Account or Log Out
Cancer Health Cancer Health
  • Home
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Cancer Health TV
    • By Author
    • RSS Links
  • Cancer Basics
    • Cancer 101
    • Newly Diagnosed
    • Living with Cancer
    • Cancer Treatment
    • Cancer Medications
    • Breast Cancer
    • Colon Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • More Types of Cancer
    • Resources
  • Hot Topics
    • Coronavirus (COVID-19)
    • Health Equity
    • Cancer Treatment
    • Car-T Therapy
    • Caregivers
    • Chemotherapy
    • Immunotherapy
    • Marijuana
    • Mental Health
    • Quality of Life
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Cancer Health Focus
    • Bulk Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Cancer Health Stories
    • Cancer Health Forums
    • Ask Cancer Health
    • Polls
    • Surveys
    • Quizzes
    • Calendar
    • Volunteer Jobs
    • Bookstore
    • Amazon Store
  • About Us
    • About Us
    • Masthead
    • Advertise
    • Awards
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Rituxan

Tweet
  • Share

Rituxan

Targeted Treatment for Leukemia

Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.

Jennifer Woyach, MD

Imbruvica Bests Chemotherapy for Older People With Leukemia

Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.

How New Drugs Become Available to More Patients

Filling in the unknowns on the balance between risk and benefit

Red and white blood cells

Targeted Therapies Improve Outcomes for People With Chronic Lymphocytic Leukemia

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.

Red and white blood cells

Maintenance Therapy Reduces Progression in People With Leukemia

Revlimid improves outcomes for chronic lymphocytic leukemia patients, but better drugs are now available.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.